VV 207
Alternative Names: VV-207Latest Information Update: 20 Jan 2026
At a glance
- Originator Vigonvita Life Sciences
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Adenovirus infections
Most Recent Events
- 20 Jan 2026 Preclinical trials in Adenovirus infections in China (unspecified route), before January 2026 (Vigonvita Life Sciences pipeline, January 2026)
- 20 Jan 2026 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Adenovirus infections released by Vigonvita Life Sciences, before January 2026 (Vigonvita Life Sciences website, January 2026)